Marker Therapeutics/ US57055L1070 /
| 2024-06-12 9:58:06 PM | Chg. - | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 4.00USD | - | 25 Turnover: 99.96 |
-Bid Size: - | -Ask Size: - | 4.00 | 3.96 |
GlobeNewswire
05-15
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
04-08
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data fr...
GlobeNewswire
03-22
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
GlobeNewswire
01-22
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and Internation...
GlobeNewswire
01-08
NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Tran...
GlobeNewswire
2023-12-21
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Fun...
GlobeNewswire
2023-12-11
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-...
GlobeNewswire
2023-11-09
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
GlobeNewswire
2023-09-11
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after ...
GlobeNewswire
2023-08-30
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewswire
2022-03-17
Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results
GlobeNewswire
2022-02-16
Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion
GlobeNewswire
2022-02-08
Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, Februa...
GlobeNewswire
2022-01-19
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Thera...
GlobeNewswire
2021-03-24
Biopharmaceutical and technology leaders form collaboration to promote standards and a modern patien...
